ATE553782T1 - Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung - Google Patents

Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung

Info

Publication number: ATE553782T1
Authority: AT; Austria
Prior art keywords: protein; src; yes; modified; nucleic acids
Prior art date: 1999-12-22

Application number

AT07020078T

Other languages

English (en)

Inventor

David Cheresh

Brian Eliceiri

Robert Paul

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-22

Filing date

2000-12-22

Publication date

2012-05-15

1999-12-22 Priority claimed from US09/470,881 external-priority patent/US6685938B1/en

2000-12-22 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

2012-05-15 Application granted granted Critical

2012-05-15 Publication of ATE553782T1 publication Critical patent/ATE553782T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 6
108090000623 proteins and genes Proteins 0.000 abstract 6
239000000203 mixture Substances 0.000 abstract 4
230000008728 vascular permeability Effects 0.000 abstract 4
102000039446 nucleic acids Human genes 0.000 abstract 3
108020004707 nucleic acids Proteins 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000009076 src-Family Kinases Human genes 0.000 abstract 3
108010087686 src-Family Kinases Proteins 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
229940121649 protein inhibitor Drugs 0.000 abstract 2
239000012268 protein inhibitor Substances 0.000 abstract 2
JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 abstract 1
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
WYZWZEOGROVVHK-GTMNPGAYSA-N radicicol Chemical compound C/1=C/C=C/C(=O)CC2=C(Cl)C(O)=CC(O)=C2C(=O)O[C@H](C)C[C@H]2O[C@@H]2\1 WYZWZEOGROVVHK-GTMNPGAYSA-N 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Environmental Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Ophthalmology & Optometry (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT07020078T 1999-12-22 2000-12-22 Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung ATE553782T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/470,881 US6685938B1 (en)	1998-05-29	1999-12-22	Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A	2000-03-29	2000-03-29

Publications (1)

Publication Number	Publication Date
ATE553782T1 true ATE553782T1 (de)	2012-05-15

Family

ID=27043259

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT00990365T ATE392215T1 (de)	1999-12-22	2000-12-22	Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
AT07020078T ATE553782T1 (de)	1999-12-22	2000-12-22	Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT00990365T ATE392215T1 (de)	1999-12-22	2000-12-22	Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit

Country Status (19)

Country	Link
EP (2)	EP1250155B1 (de)
JP (1)	JP2003518077A (de)
KR (1)	KR100813818B1 (de)
CN (1)	CN1434727A (de)
AT (2)	ATE392215T1 (de)
AU (1)	AU781444B2 (de)
BR (1)	BR0016547A (de)
CA (1)	CA2395136A1 (de)
CZ (1)	CZ304320B6 (de)
DE (1)	DE60038631T2 (de)
DK (2)	DK1905457T3 (de)
ES (2)	ES2383763T3 (de)
HU (1)	HU229628B1 (de)
NO (1)	NO20023036L (de)
PL (1)	PL356815A1 (de)
PT (2)	PT1905457E (de)
RU (1)	RU2271216C2 (de)
SK (1)	SK287575B6 (de)
WO (1)	WO2001045751A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030130209A1 (en) *	1999-12-22	2003-07-10	Cheresh David A.	Method of treatment of myocardial infarction
DE60120427D1 (de)	2000-08-25	2006-07-20	Sloan Kettering Inst Cancer	Radicicol und monocillin und ihre analogen und ihre anwendungen
WO2003079936A1 (en) *	2002-03-18	2003-10-02	Medtronic Ave Inc.	Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
CN1681525A (zh) *	2002-07-12	2005-10-12	曹义海	一种抑制血管渗漏和组织水肿的方法
EP1413887A1 (de) *	2002-10-22	2004-04-28	Aventis Pharma S.A.	Src Kinase Inhibitoren zur Behandlung von Alzheimer Krankheit
WO2004056386A2 (en) *	2002-12-19	2004-07-08	To-Bbb Holding B.V.	Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) *	2003-03-29	2003-05-07	Astrazeneca Ab	Therapeutic agent
ATE481134T1 (de) *	2004-01-21	2010-10-15	Univ Emory	Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
US20060094682A1 (en) *	2004-10-29	2006-05-04	Odyssey Thera, Inc.	Kinase inhibitors for the treatment of diabetes and obesity
JP2009521510A (ja) *	2005-12-23	2009-06-04	アルコン，インコーポレイテッド	眼への受容体チロシンキナーゼ阻害（ｒｔｋｉ）化合物の送達のための医薬製剤
NZ594457A (en) *	2006-05-22	2013-06-28	Univ California	Compositions and methods for the delivery of oxygen
ES2318616T3 (es) *	2006-06-01	2009-05-01	Cellzome Ag	Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
DE102007037008B4 (de) *	2007-08-06	2015-09-10	Siemens Aktiengesellschaft	Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
CN102656153B (zh) *	2009-10-29	2015-02-18	延世大学校产学协力团	新型血管渗漏阻断剂
RU2419418C1 (ru) *	2009-11-16	2011-05-27	Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК")	Состав для удаления содержимого из атеросклеротических отложений в артериях человека
US8557513B2 (en) *	2011-06-27	2013-10-15	Biocrine Ab	Methods for treating and/or limiting development of diabetes
WO2014152122A2 (en) *	2013-03-15	2014-09-25	Children's Medical Center Corporation	Methods of altering vascular permeability and uses thereof
CN105311645B (zh) *	2015-01-23	2018-11-30	中国人民解放军第二军医大学	胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用
CN105288654B (zh) *	2015-01-23	2018-11-30	中国人民解放军第二军医大学	蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4356167A (en)	1978-01-27	1982-10-26	Sandoz, Inc.	Liposome drug delivery systems
US5092885A (en)	1987-02-12	1992-03-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Peptides with laminin activity
US5112946A (en)	1989-07-06	1992-05-12	Repligen Corporation	Modified pf4 compositions and methods of use
US5542935A (en)	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US5580575A (en)	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
US5192744A (en)	1990-01-12	1993-03-09	Northwestern University	Method of inhibiting angiogenesis of tumors
WO1991011719A1 (en) *	1990-01-26	1991-08-08	Washington Research Foundation	Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy
ATE130517T1 (de)	1990-08-08	1995-12-15	Takeda Chemical Industries Ltd	Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
US5912170A (en) *	1991-03-07	1999-06-15	The General Hospital Corporation	Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5753230A (en)	1994-03-18	1998-05-19	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
GB9417366D0 (en) *	1994-08-26	1994-10-19	Prolifix Ltd	Cell cycle regulated repressor and DNA element
US5643599A (en)	1995-06-07	1997-07-01	President And Fellows Of Harvard College	Intracellular delivery of macromolecules
US5922697A (en) *	1996-10-02	1999-07-13	Warner-Lambert Company	Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
JP2002511852A (ja) *	1997-05-07	2002-04-16	スージェン・インコーポレーテッド	蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
US6723694B1 (en) *	1997-05-21	2004-04-20	The Children's Medical Center Corp.	Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) *	1997-06-13	2002-07-16	New York University Medical Center	Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CN1278724A (zh) *	1997-10-06	2001-01-03	巴斯福股份公司	抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
MXPA00011821A (es) *	1998-05-29	2004-07-30	Scripps Research Inst	Metodos y composiciones utiles para la modulacion de la angiogenesis usando tirosina-cinasa src.
JP2002529421A (ja) *	1998-11-06	2002-09-10	ビーエーエスエフアクチェンゲゼルシャフト	血管過浸透性の阻害方法

2000
- 2000-12-22 EP EP00990365A patent/EP1250155B1/de not_active Expired - Lifetime
- 2000-12-22 ES ES07020078T patent/ES2383763T3/es not_active Expired - Lifetime
- 2000-12-22 BR BR0016547-6A patent/BR0016547A/pt not_active Application Discontinuation
- 2000-12-22 AT AT00990365T patent/ATE392215T1/de active
- 2000-12-22 DE DE60038631T patent/DE60038631T2/de not_active Expired - Lifetime
- 2000-12-22 PT PT07020078T patent/PT1905457E/pt unknown
- 2000-12-22 PT PT00990365T patent/PT1250155E/pt unknown
- 2000-12-22 CA CA002395136A patent/CA2395136A1/en not_active Abandoned
- 2000-12-22 DK DK07020078.7T patent/DK1905457T3/da active
- 2000-12-22 DK DK00990365T patent/DK1250155T3/da active
- 2000-12-22 HU HU0203957A patent/HU229628B1/hu not_active IP Right Cessation
- 2000-12-22 SK SK849-2002A patent/SK287575B6/sk not_active IP Right Cessation
- 2000-12-22 KR KR1020027008102A patent/KR100813818B1/ko not_active Expired - Fee Related
- 2000-12-22 CZ CZ2002-2156A patent/CZ304320B6/cs not_active IP Right Cessation
- 2000-12-22 ES ES00990365T patent/ES2303514T3/es not_active Expired - Lifetime
- 2000-12-22 JP JP2001546690A patent/JP2003518077A/ja active Pending
- 2000-12-22 WO PCT/US2000/035396 patent/WO2001045751A1/en not_active Ceased
- 2000-12-22 PL PL00356815A patent/PL356815A1/xx not_active Application Discontinuation
- 2000-12-22 EP EP07020078A patent/EP1905457B1/de not_active Expired - Lifetime
- 2000-12-22 RU RU2002119399/15A patent/RU2271216C2/ru not_active IP Right Cessation
- 2000-12-22 AU AU27400/01A patent/AU781444B2/en not_active Ceased
- 2000-12-22 CN CN00819151A patent/CN1434727A/zh active Pending
- 2000-12-22 AT AT07020078T patent/ATE553782T1/de active
2002
- 2002-06-21 NO NO20023036A patent/NO20023036L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR100813818B1 (ko)	2008-03-17
PL356815A1 (en)	2004-07-12
WO2001045751A1 (en)	2001-06-28
KR20020063259A (ko)	2002-08-01
RU2271216C2 (ru)	2006-03-10
EP1905457A1 (de)	2008-04-02
DE60038631D1 (de)	2008-05-29
EP1905457B1 (de)	2012-04-18
DK1905457T3 (da)	2012-05-29
ES2383763T3 (es)	2012-06-26
ES2303514T3 (es)	2008-08-16
PT1250155E (pt)	2008-06-06
AU2740001A (en)	2001-07-03
CZ304320B6 (cs)	2014-03-05
HU229628B1 (en)	2014-03-28
HUP0203957A2 (hu)	2003-03-28
HUP0203957A3 (en)	2005-07-28
EP1250155B1 (de)	2008-04-16
DK1250155T3 (da)	2008-08-25
BR0016547A (pt)	2002-10-29
DE60038631T2 (de)	2009-06-10
SK287575B6 (sk)	2011-03-04
AU781444B2 (en)	2005-05-26
PT1905457E (pt)	2012-05-25
SK8492002A3 (en)	2002-11-06
EP1250155A1 (de)	2002-10-23
CN1434727A (zh)	2003-08-06
JP2003518077A (ja)	2003-06-03
ATE392215T1 (de)	2008-05-15
RU2002119399A (ru)	2004-02-27
EP1250155A4 (de)	2003-08-20
CA2395136A1 (en)	2001-06-28
NO20023036D0 (no)	2002-06-21
NO20023036L (no)	2002-07-22

Publication	Publication Date	Title
ATE553782T1 (de)	2012-05-15	Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
DE60010234D1 (de)	2004-06-03	2-amino-6-anilino-purine und deren verwendung als arzneimittel
CA2366932A1 (en)	2000-10-26	Cyclic protein tyrosine kinase inhibitors
CY1108813T1 (el)	2014-04-09	Αναστολεις κινασων τυροσινης
NO20030381L (no)	2003-02-24	Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
BR0116452A (pt)	2003-09-30	Composto, composição farmacêutica, uso de um composto
DE60037211D1 (de)	2008-01-03	Indazol-Verbindungen und Pharmazeutische Zusammensetzungen zur Hemmung von Proteinkinase und Verfahren zu ihrer Verwendung
NO20002121L (no)	2000-05-09	Benzotiazol-protein-tyrosin-kinaseinhibitorer
CY1106386T1 (el)	2011-10-12	Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
ATE341545T1 (de)	2006-10-15	Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
MXPA04001328A (es)	2004-05-05	Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
ATE279410T1 (de)	2004-10-15	3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
DE60108626D1 (de)	2005-03-03	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE213944T1 (de)	2002-03-15	Verwendung von immunomodulatoren
ECSP055537A (es)	2005-03-10	Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino
DE60221275D1 (de)	2007-08-30	Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
EP1663201A4 (de)	2009-10-28	Verwendung von neuen 2-oxo-heterozyklischen verbindungen sowie diesen enthaltenden pharmazeutischen zubereitungen
DE69916488D1 (de)	2004-05-19	Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
WO2001079167A3 (en)	2002-02-28	Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
MXPA04000272A (es)	2004-05-04	Derivados de 4-aminociclohexanol sustituidos.
DE60233030D1 (de)	2009-09-03	Tartrat- und phosphatsalz von 3,4-diaminopyridin, pharmazeutische zusammensetzung und deren verwendung
DE60104577D1 (de)	2004-09-09	Verwendung von mono- und bifunktionalen (Per)Fluoropolyetherderivaten zur Behandlung von keramischen Werkstoffen
ATE272400T1 (de)	2004-08-15	Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
BRPI0416777A (pt)	2007-04-17	composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase